The NIH has announced a drastic reduction in the indirect cost reimbursement rates for research grants from negotiated averages near 30% to just 15%. This change will impact both new and existing grants retroactively, and it comes without prior notice, creating potential financial turmoil for biomedical research institutions reliant on these funds. The shift is justified through federal regulations but raises questions about legality given the abrupt nature of its implementation. Many institutions are now facing severe budgetary constraints due to this unexpected policy change.
The new policy imposed by NIH cuts indirect funding rates for biomedical research grants to 15%, down from negotiated amounts averaging close to 30%.
This unilateral decision, with no prior warning, threatens the financial viability of countless research institutions relying on indirect costs for essential operational support.
Collection
[
|
...
]